TrialCurrent oncology (Toronto, Ont.)2023

Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack Years.

Ali Silver et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.